<?xml version="1.0"?>
<rss version="2.0">
   <channel>
      <title>HNN215 Week 7 3pm by </title>
      <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07</link>
      <description>Management of patients experiencing GIT and cellular dysfunction</description>
      <language>en-us</language>
      <pubDate>2023-08-28 01:54:49 UTC</pubDate>
      <lastBuildDate>2023-08-29 05:48:11 UTC</lastBuildDate>
      <webMaster>hello@padlet.com</webMaster>
      <image>
         <url></url>
      </image>
      <item>
         <title>Case scenario</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485781</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/6aad18d0b69d7bdfdda07e1ee688b46f/image.png" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485781</guid>
      </item>
      <item>
         <title>Scenario continued</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485782</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/3e0e6bc0194301befd19fd3235f86183/image.png" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485782</guid>
      </item>
      <item>
         <title></title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485784</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/79b8566737b271343b953a794deecf6f/HNN215_week_7_NIMC_2023.pdf" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485784</guid>
      </item>
      <item>
         <title></title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485786</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/b532cd96c4cabf69e3eeff08b72b3c77/Nurse_initiated_drug_policy_Deakin_Hospital_2023.pdf" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485786</guid>
      </item>
      <item>
         <title>Compare and contrast the significant risks for Tamoxifen</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485787</link>
         <description><![CDATA[<div>What were your significant risks Tamoxifen? Are you able to group these risks?  Why are they significant?<br>Do you understand the MoA of how the patient might develop the risks? <br>Did you need to go and look them up again? </div>]]></description>
         <enclosure url="" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485787</guid>
      </item>
      <item>
         <title>Significant risks / drug-drug interactions???                           </title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485788</link>
         <description><![CDATA[<div>How / why does it occur?<br>What are they and what signs and symptoms would we see?<br>What do we as nurses do;<br>- prevent and/ or manage these?</div>]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/42ddb2ddb072cf39979f8cde7f343166/image.png" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485788</guid>
      </item>
      <item>
         <title>Group 1</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485790</link>
         <description><![CDATA[<div>Naproxen<br><br><strong>Class:NSAID's<br>MOA:</strong>Naproxen blocks arachidonate binding to competitively inhibit both cyclooxygenase (COX) isoenzymes, COX-1 and COX-2, resulting in analgesic and anti-inflammatory effects.<br><strong>Signs and symptoms: </strong>Paget's disease , acute gout, spondylitis, RA, pain and primary dysmenorrhea.<br><strong>Drug to drug interactions</strong>:ACE inhibitors (such as captopril, lisinopril), angiotensin II receptor blockers (such as losartan, valsartan), cidofovir, corticosteroids (such as prednisone), lithium, "water pills" (diuretics such as furosemide)<br><strong>How to prevent, assess or manage risks/nursing considerations: </strong>The lowest possible dose should be used for the shortest possible duration<strong>.</strong>Patients taking naproxen should receive monitoring for pain relief, significant changes in blood pressure, worsening kidney function, and GI symptoms such as gastroesophageal reflux disease (GERD), abdominal pain, or melena. For patients on chronic NSAID therapy, periodic monitoring with complete blood counts to assess for anemia and chemistry panels to evaluate kidney and liver function merit consideration. Also, educate the patient regarding interaction of medicines with other drug&nbsp; such as vitamins or herbs.<strong><br><br>Tamoxifen:<br>MOA:</strong>It selectively binds to estrogen receptors, producing both estrogenic and anti-estrogen effects<br><strong>Risks:</strong>It can increases the risk of cancer of the uterus including endometrium cancer and uterine sarcoma.</div>]]></description>
         <enclosure url="" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485790</guid>
      </item>
      <item>
         <title>Group 2</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485791</link>
         <description><![CDATA[<div>Ondansetron<br><br><strong>Class: </strong>5HT3 antagonists<strong><br>MOA: </strong>Central and peripheral 5HT3 receptor blockade.<strong><br>Signs and symptoms:</strong><br>- Nausea <br>- Vomiting<strong><br>Drug to drug interactions:</strong><br>- tramdole<br>- apomorphine <br>- rifampicin<strong><br>How to prevent, assess or manage risks/nursing considerations:<br>- </strong>monitor GI<br>- falls risk assessment <br>- check motor function<br>- monitor liver function?<br>- 4-8 max of 24 dose<strong><br><br>Tamoxifen: </strong>Selective estrogen receptor modulators <strong><br>MOA:</strong> Compete with estrogen for receptor sites in breast tissue (anti-estrogenic effect) inhibiting tumour growth. Also have estrogen agonist activity on endometrium, bone and lipids. Suppression of other growth factors and cytokines may occur.<strong><br>Risks: (common side effects)<br></strong>- leg cramps<br>- alopecia<br>- hot flushes<br>- sweating<br>- vaginal discharge<br>- nausea<br>- oedema<br>- increase in hepatic enzymes and bilirubin<br>- fatty liver<br>- uterine polyps</div>]]></description>
         <enclosure url="" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485791</guid>
      </item>
      <item>
         <title>Group 3</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485792</link>
         <description><![CDATA[<div>Panadol Osteo<br><br><strong>Class: </strong>Non-Narcotic Analgesia<strong><br>MOA: </strong>Inhibition of prostoglandin synthesis indicated for mild-moderate pain. Also has an antipyretic effect.<strong><br>Signs and symptoms:&nbsp; </strong>liver damage<strong><br>Drug to drug interactions:<br>How to prevent, assess or manage risks/nursing considerations: </strong>Educate patient on dosage amounts to reduce risk of overdose<strong><br><br>Tamoxifen:<br>MOA:<br>Risks:</strong></div>]]></description>
         <enclosure url="" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485792</guid>
      </item>
      <item>
         <title>Group 4</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485794</link>
         <description><![CDATA[<div>Morphine<br><br><strong>Class:&nbsp;<br>MOA: <br>Signs and symptoms:<br><br>Drug to drug interactions:<br>How to prevent, assess or manage risks/nursing considerations:<br><br>Tamoxifen:<br>MOA:<br>Risks:</strong></div>]]></description>
         <enclosure url="" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485794</guid>
      </item>
      <item>
         <title>Group 5</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485795</link>
         <description><![CDATA[<div>Esomeprazole<br><br><strong>Class: </strong>Proton pump inhibitor<strong><br>MOA:&nbsp; </strong>Binds to the proton pump and inhibits acid (HCL) secretion<strong><br>Signs and symptoms:&nbsp; </strong>headache, N&amp;V, diarrhoea, abdominal pain and constipation <strong><br>Drug to drug interactions: </strong>catalopram, tacrolimus and enzalutamide<strong><br>How to prevent, assess or manage risks/nursing considerations:<br></strong>- GIT disturbances: Avoid alcohol and foods that may cause an increase in GI irritation<br>- Electrolyte disturbances: maintain adequate fluid balance, monitor electrolyte levels, signs of hyponatremia/hypomagnesemia<br>- Risk of accumulation: monitor for adverse effects when higher doses are used in hepatic impairment<strong><br><br>Tamoxifen:<br>MOA:&nbsp; </strong>competes with oestrogen/oestradiol to bind to receptors in the breast tissue, thereby inhibiting tumour growth<strong><br>Risks: </strong>advise pt to warn you or the doc if they experience any abnormal vaginal bleeding, discharge, or pain and pressure in the pelvic region while taking tamoxifen or when stop taking it.&nbsp;</div>]]></description>
         <enclosure url="" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485795</guid>
      </item>
      <item>
         <title>Group 1</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485796</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485796</guid>
      </item>
      <item>
         <title>Group 2</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485797</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485797</guid>
      </item>
      <item>
         <title>Group 3</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485798</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485798</guid>
      </item>
      <item>
         <title>Group 4</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485799</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485799</guid>
      </item>
      <item>
         <title>Group 5</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485800</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485800</guid>
      </item>
      <item>
         <title>Consider Mrs Marple&#39;s situation...</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485801</link>
         <description><![CDATA[<div><strong><mark>Note: Always consider:<br>Is there anything in the patient's condition/ past history that may increase the risks?</mark></strong></div>]]></description>
         <enclosure url="" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485801</guid>
      </item>
      <item>
         <title>Scenario addition</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485804</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/f989733a8e542412426f9c854cf8a57a/image.png" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485804</guid>
      </item>
      <item>
         <title>Nurse initiated medication</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485805</link>
         <description><![CDATA[<div><strong>Mrs Marple now has constipation. What medication/s will you give her to relieve this?</strong><br><em>Deakin Hospital Protocol needs to be considered for this decision</em></div>]]></description>
         <enclosure url="https://i.ytimg.com/vi/grQdTmdaQY0/maxresdefault.jpg" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485805</guid>
      </item>
      <item>
         <title>Aged patients and medications</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485807</link>
         <description><![CDATA[<div>What factors may result in impaired medication effects in these patients?</div>]]></description>
         <enclosure url="https://image.slideserve.com/1208289/clinical-pharmacokinetics-l.jpg" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485807</guid>
      </item>
      <item>
         <title>Group 1</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485808</link>
         <description><![CDATA[<ul><li>&nbsp;physiological changes can affect the way our body metabolises drugs, causing adverse reactions.&nbsp;</li><li>Older people are more likely to be taking multiple medications (‘polypharmacy’), which increases the risk of medications being implicated in hospital admissions.&nbsp;</li><li>Up to 30 per cent of hospital admissions of people aged 65 years and over are medication-related, and approximately half of these could be prevented<sup>1</sup>.&nbsp;</li><li>Medication-related admissions in older people can be caused by adverse drug reactions, failure to take a prescribed medication and errors with taking medications.</li></ul><div><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485808</guid>
      </item>
      <item>
         <title>Group 2</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485809</link>
         <description><![CDATA[<div>- body fat (increases the volume of distribution for highly lipophilic drugs (eg, diazepam, chlordiazepoxide) and may meaningfully increase their elimination half-lives.)<br>- metabolism rate&nbsp;<br>- total body water and muscle mass are decreased<br>- greater risk of dehydration&nbsp;<br>- may refuse nutrition&nbsp;<br>- refusing medication&nbsp;<br>- more likely to experience adverse drug reactions&nbsp;<br>- education<br>- reduced gastric acidicy&nbsp;<br>- general reduction in blood flow<br>- thinner skin, faster topical absorption<br>- loss of muscle ton, affects distribution<br>- liver decreased binding capability&nbsp;<br>- more likely to experience medication toxicity </div>]]></description>
         <enclosure url="" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485809</guid>
      </item>
      <item>
         <title>Group 4</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485810</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485810</guid>
      </item>
      <item>
         <title>Group 3</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485811</link>
         <description><![CDATA[<div>physiological changes such as:&nbsp;<br>- increased body fat<br>- decreased body water&nbsp;<br>- decreased muscle mass&nbsp;<br>- changes in renal and liver function<br>these changes can affect the way the body absorbs, distributes, metabolises and eliminates drugs. </div>]]></description>
         <enclosure url="" />
         <pubDate>2023-08-28 01:54:49 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674485811</guid>
      </item>
      <item>
         <title>Group 5 </title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674736860</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-08-28 05:48:32 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/jjpwnwyfrflwii07/wish/2674736860</guid>
      </item>
   </channel>
</rss>
